Tyvin A Rich

Summary

Affiliation: University of Virginia
Country: USA

Publications

  1. pmc Weekly paclitaxel, gemcitabine, and external irradiation followed by randomized farnesyl transferase inhibitor R115777 for locally advanced pancreatic cancer
    Tyvin A Rich
    The Cancer Center, University of Virginia Health System West, University of Virginia, Charlottesville, VA, USA
    Onco Targets Ther 5:161-70. 2012
  2. ncbi request reprint Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy
    Tyvin A Rich
    FACR, Department of Radiation Oncology, University of Virginia Health System, PO Box 800383, Charlottesville, VA 22908 0383, USA
    J Clin Oncol 22:2214-32. 2004
  3. ncbi request reprint Chemoradiotherapy for gastrointestinal cancers
    Tyvin A Rich
    Department of Radiation Oncology, University of Virginia, PO Box 800383, Charlottesville, VA 22908, USA
    Curr Oncol Rep 7:196-202. 2005
  4. ncbi request reprint Symptom clusters in cancer patients and their relation to EGFR ligand modulation of the circadian axis
    Tyvin A Rich
    Department of Radiation Oncology, University of Virginia Health Sciences Center, PO Box 800383, Charlottesville, VA 22901, USA
    J Support Oncol 5:167-74; discussion 176-7. 2007
  5. ncbi request reprint COX-2 inhibitors as radiation sensitizers for upper GI tract cancers: esophagus, stomach, and pancreas
    Tyvin A Rich
    Department of Radiation Oncology, University of Virginia Health Sciences System, Charlottesville 22901, USA
    Am J Clin Oncol 26:S110-3. 2003
  6. doi request reprint Analyzing the symptoms in cancer patients. Disrupted circadian signaling by the epidermal growth factor receptor
    Tyvin A Rich
    Department of Radiation Oncology, University of Virginia, Charlottesville, VA 22908, USA
    IEEE Eng Med Biol Mag 27:25-8. 2008
  7. ncbi request reprint Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer
    Tyvin Rich
    Department of Radiation Oncology, University of Virginia Health System, Charlottesville, VA, USA
    Clin Cancer Res 11:1757-64. 2005
  8. ncbi request reprint Chronomodulated chemotherapy and irradiation: an idea whose time has come?
    Tyvin A Rich
    Department of Radiation Oncology, University of Virginia Health System, Charlottesville 22908, USA
    Chronobiol Int 19:191-205. 2002
  9. ncbi request reprint Modulation of dose intensity in aerodigestive tract cancers: strategies to reduce toxicity
    T A Rich
    Department of Radiation Oncology, University of Virginia Health Sciences Center, Charlottesville 22908, USA
    Oncology (Williston Park) 15:1603-9, 1613; discussion 1614-8, 1621-2. 2001
  10. pmc Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial
    William F Regine
    Department of Radiation Oncology, University of Maryland, Baltimore, MD, USA
    Ann Surg Oncol 18:1319-26. 2011

Collaborators

Detail Information

Publications34

  1. pmc Weekly paclitaxel, gemcitabine, and external irradiation followed by randomized farnesyl transferase inhibitor R115777 for locally advanced pancreatic cancer
    Tyvin A Rich
    The Cancer Center, University of Virginia Health System West, University of Virginia, Charlottesville, VA, USA
    Onco Targets Ther 5:161-70. 2012
    ....
  2. ncbi request reprint Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy
    Tyvin A Rich
    FACR, Department of Radiation Oncology, University of Virginia Health System, PO Box 800383, Charlottesville, VA 22908 0383, USA
    J Clin Oncol 22:2214-32. 2004
    ..Fluorouracil (FU) chemoradiotherapy has demonstrated success in several organ sites with multiple dosing schedules that now guide the selection of oral analogs of FU to provide new chemoradiotherapy options...
  3. ncbi request reprint Chemoradiotherapy for gastrointestinal cancers
    Tyvin A Rich
    Department of Radiation Oncology, University of Virginia, PO Box 800383, Charlottesville, VA 22908, USA
    Curr Oncol Rep 7:196-202. 2005
    ....
  4. ncbi request reprint Symptom clusters in cancer patients and their relation to EGFR ligand modulation of the circadian axis
    Tyvin A Rich
    Department of Radiation Oncology, University of Virginia Health Sciences Center, PO Box 800383, Charlottesville, VA 22901, USA
    J Support Oncol 5:167-74; discussion 176-7. 2007
    ....
  5. ncbi request reprint COX-2 inhibitors as radiation sensitizers for upper GI tract cancers: esophagus, stomach, and pancreas
    Tyvin A Rich
    Department of Radiation Oncology, University of Virginia Health Sciences System, Charlottesville 22901, USA
    Am J Clin Oncol 26:S110-3. 2003
    ..The addition of a cyclooxygenase-2 (COX-2) inhibitor is being investigated in upper gastrointestinal cancer sites because there is a high degree of overexpression of COX-2 in these cancers...
  6. doi request reprint Analyzing the symptoms in cancer patients. Disrupted circadian signaling by the epidermal growth factor receptor
    Tyvin A Rich
    Department of Radiation Oncology, University of Virginia, Charlottesville, VA 22908, USA
    IEEE Eng Med Biol Mag 27:25-8. 2008
  7. ncbi request reprint Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer
    Tyvin Rich
    Department of Radiation Oncology, University of Virginia Health System, Charlottesville, VA, USA
    Clin Cancer Res 11:1757-64. 2005
    ..In this study, the role of circulating cytokines in the production symptoms in cancer patients is evaluated...
  8. ncbi request reprint Chronomodulated chemotherapy and irradiation: an idea whose time has come?
    Tyvin A Rich
    Department of Radiation Oncology, University of Virginia Health System, Charlottesville 22908, USA
    Chronobiol Int 19:191-205. 2002
    ....
  9. ncbi request reprint Modulation of dose intensity in aerodigestive tract cancers: strategies to reduce toxicity
    T A Rich
    Department of Radiation Oncology, University of Virginia Health Sciences Center, Charlottesville 22908, USA
    Oncology (Williston Park) 15:1603-9, 1613; discussion 1614-8, 1621-2. 2001
    ..This approach may be beneficial in the elderly and those medically unfit to tolerate traditional dose-intense combined-modality schedules. Further evaluation of this concept is warranted, based on existing data...
  10. pmc Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial
    William F Regine
    Department of Radiation Oncology, University of Maryland, Baltimore, MD, USA
    Ann Surg Oncol 18:1319-26. 2011
    ..The impact of the addition of gemcitabine to 5-fluorouracil (5-FU) chemoradiation (CRT) on 5-year overall survival (OS) in resected pancreatic adenocarcinoma are presented with updated results of a phase III trial...
  11. pmc Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas
    Ross A Abrams
    Department of Radiation Oncology, Rush University Medical Center, Chicago, IL 60612, USA
    Int J Radiat Oncol Biol Phys 82:809-16. 2012
    ..5FU-RT treatment was preceded and followed by randomly assigned chemotherapy, either 5-FU or gemcitabine. This analysis explored whether failure to adhere to specified RT guidelines influenced survival and/or toxicity...
  12. pmc Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411
    Christopher H Crane
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 27:4096-102. 2009
    ..Secondary end points were toxicity, progression-free survival (PFS), and response rate (RR)...
  13. doi request reprint Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial
    William F Regine
    Department of Radiation Oncology, University of Maryland Medical Center, Baltimore 21030, USA
    JAMA 299:1019-26. 2008
    ..Among patients with locally advanced metastatic pancreatic adenocarcinoma, gemcitabine has been shown to improve outcomes compared with fluorouracil...
  14. doi request reprint Preoperative chemoradiation for rectal cancer using capecitabine and celecoxib correlated with posttreatment assessment of thymidylate synthase and thymidine phosphorylase expression
    Keith R Unger
    Department of Radiation Oncology, University of Virginia, Charlottesville, Virginia 22908, USA
    Int J Radiat Oncol Biol Phys 80:1377-82. 2011
    ..The toxicity, efficacy, surgical morbidity, and immunohistochemical TS and TP expression were assessed in surgical resection specimens after preoperative chemoradiation...
  15. doi request reprint Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer
    Jayme B Stokes
    Department of Surgery, University of Virginia Health System, Charlottesville, VA, USA
    Ann Surg Oncol 18:619-27. 2011
    ..Patients with borderline resectable pancreatic ductal adenocarcinoma (PDA) represent a high-risk group of patients due to tumor or patient-related characteristics. The optimal management of these patients has not been fully defined...
  16. ncbi request reprint Clinical experience with chronomodulated infusional 5-fluorouracil chemoradiotherapy for pancreatic adenocarcinoma
    Kimberly S Keene
    Department of Radiation Oncology, University of Virginia Health Science Center, Charlottesville, VA 22908, USA
    Int J Radiat Oncol Biol Phys 62:97-103. 2005
    ..To evaluate retrospectively the efficacy and chronic toxicities of concurrent radiotherapy and chronomodulated infusion 5-fluorouracil (5-FU) in patients with pancreatic adenocarcinoma...
  17. ncbi request reprint Clinical research in pancreatic cancer: the Radiation Therapy Oncology Group trials
    Christopher G Willett
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Int J Radiat Oncol Biol Phys 56:31-7. 2003
    ..This report summarizes current and future Radiation Therapy Oncology Group clinical trials in the treatment of patients with localized pancreatic cancer...
  18. doi request reprint Accelerated treatment using intensity-modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinoma
    Alyson McIntosh
    Department of Radiation Oncology, University of Virginia Health System, Charlottesville, Virginia, USA
    Cancer 115:5117-25. 2009
    ..In this study, the authors investigated the feasibility, toxicity, and efficacy associated with intensity-modulated radiation therapy (IMRT) and concurrent, chronomodulated capecitabine in the treatment of unresectable HCC...
  19. ncbi request reprint Recursive partitioning analysis of pretreatment variables of 416 patients with locoregional esophageal cancer treated with definitive concomitant chemoradiotherapy on Intergroup and Radiation Therapy Oncology Group trials
    Charles R Thomas
    Department of Radiation Oncology, The University of Texas Health Science Center, San Antonio, TX 78229 3900, USA
    Int J Radiat Oncol Biol Phys 58:1405-10. 2004
    ....
  20. doi request reprint Unresectable cholangiocarcinoma: comparison of survival in biliary stenting alone versus stenting with photodynamic therapy
    Michel Kahaleh
    Digestive Health Center, University of Virginia Health System, Charlottesville, Virginia 22908 0708, USA
    Clin Gastroenterol Hepatol 6:290-7. 2008
    ..We compared survival in patients with unresectable cholangiocarcinoma undergoing endoscopic retrograde cholangiopancreatography (ERCP) with PDT and stent placement with a group undergoing ERCP with stent placement alone...
  21. ncbi request reprint Preirradiation PSA predicts biochemical disease-free survival in patients treated with postprostatectomy external beam irradiation
    C H Crane
    The University of Virginia Health Sciences Center Department of Therapeutic Radiology and Oncology, Charlottesville 22908, USA
    Int J Radiat Oncol Biol Phys 39:681-6. 1997
    ....
  22. ncbi request reprint A pilot study of chronomodulated infusional 5-fluorouracil chemoradiation for pancreatic cancer
    D R Penberthy
    Department of Radiation Oncology, University of Virginia Health Sciences Center, Charlottesville 22901, USA
    Ann Oncol 12:681-4. 2001
    ..This method may warrant further examination, as it may be attractive for the elderly or those who cannot tolerate the toxicity associated with standard post-operative treatment protocols...
  23. ncbi request reprint Covered self-expandable metal stents in pancreatic malignancy regardless of resectability: a new concept validated by a decision analysis
    M Kahaleh
    Digestive Health Center, University of Virginia Health System, Charlottesville, Virginia 22908 0708, USA
    Endoscopy 39:319-24. 2007
    ..We analyzed the efficacy and cost-effectiveness of covered SEMS (CSEMS) in patients with pancreatic cancer and distal biliary obstruction without regard to surgical resectability...
  24. ncbi request reprint Nuclear scintigraphic assessment of intestinal dysfunction after combined treatment with 9-amino-20(S)-camptothecin (9-AC) and irradiation
    A V Kirichenko
    Department of Radiation Oncology, University of Virginia, Charlottesville, VA 22908, USA
    Int J Radiat Oncol Biol Phys 47:1043-9. 2000
    ..We also correlated the absorption data with morphologic changes in the jejunal mucosa...
  25. ncbi request reprint Postoperative adjuvant therapy for pancreatic cancer
    David R Penberthy
    Department of Radiation Oncology, University of Virginia Health System, Charlottesville, Virginia 22908, USA
    Semin Surg Oncol 21:256-60. 2003
    ..The recent trials reviewed here varied considerably in terms of the total dose and technique used, and the choice of radiation sensitizing treatment...
  26. ncbi request reprint Infusional chemoradiation for rectal and anal cancers
    T A Rich
    Department of Radiation Oncology, University of Virginia Health Sciences Center, Charlottesville, USA
    Oncology (Williston Park) 13:131-4. 1999
    ....
  27. ncbi request reprint Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis
    Leonard L Gunderson
    Department of Radiation Oncology, Mayo Clinic Scottsdale, Scottsdale, AZ 85259, USA
    Int J Radiat Oncol Biol Phys 54:386-96. 2002
    ..To determine the rates of survival and disease control by TNM and MAC stage in three randomized North American rectal adjuvant studies...
  28. ncbi request reprint Camptothecin schedule and timing of administration with irradiation
    T A Rich
    Department of Radiation Oncology, University of Virginia Health System, Charlottesville, Virginia, USA
    Oncology (Williston Park) 15:37-41. 2001
    ..One novel approach (based on preclinical observations) with the potential to widen the therapeutic window may be the use of a chronomodulated camptothecin delivery schedule with irradiation...
  29. doi request reprint Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Mail Stop 426, Houston, Texas 77030, USA
    JAMA 299:1914-21. 2008
    ..Chemoradiation as definitive therapy is the preferred primary therapy for patients with anal canal carcinoma; however, the 5-year disease-free survival rate from concurrent fluorouracil/mitomycin and radiation is only approximately 65%...
  30. ncbi request reprint Acute diarrhea during adjuvant therapy for rectal cancer: a detailed analysis from a randomized intergroup trial
    Robert C Miller
    North Central Cancer Treatment Group, Coordinating Center, Rochester, MN, USA
    Int J Radiat Oncol Biol Phys 54:409-13. 2002
    ..Toxicity from a previously reported randomized clinical trial was analyzed to quantify the difference in this risk. Additionally, the persistence of diarrhea after RT was analyzed...
  31. ncbi request reprint Cancer symptom complexes related to alterations in molecular circadian axis signaling
    Tyvin A Rich
    Conf Proc IEEE Eng Med Biol Soc 1:171-2. 2006
    ....
  32. ncbi request reprint Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response
    Jaffer A Ajani
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 24:3953-8. 2006
    ..We hypothesized that, in a cooperative group setting, preoperative chemoradiotherapy would induce a 20% pathologic complete response (pathCR) rate. Combined-modality therapy quality, survival, and safety were secondary end points...
  33. ncbi request reprint Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144
    Stephen R Smalley
    Kansas City Community Clinical Oncology Program CCOP, Kansas City, KS, USA
    J Clin Oncol 24:3542-7. 2006
    ..Adjuvant chemoradiotherapy after or before resection of high-risk rectal cancer improves overall survival (OS) and pelvic control. We studied three postoperative fluorouracil (FU) radiochemotherapy regimens...
  34. ncbi request reprint Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis
    Leonard L Gunderson
    Radiation Oncology Department, Mayo Clinic Cancer Center, Scottsdale, AZ 85259, USA
    J Clin Oncol 22:1785-96. 2004
    ..To determine survival and relapse rates by T and N stage and treatment method in five randomized phase III North American rectal adjuvant studies...